STAT+: Palantir’s small but growing health-software business leans on meeting customers’ demands
PALO ALTO, Calif. — At a bustling artificial intelligence conference in June hosted by data…
Category: STAT+
FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline
The Food and Drug Administration on Thursday granted full approval to the first therapy for…
STAT+: Pharmalittle: Next big hope for Alzheimer’s might not help most Black patients; drugmakers ask Supreme Court to toss terrorism-support ruling
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: From ‘Jeopardy!’ to Politico, the PBM ad wars are taking over D.C.
WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager…
STAT+: What to know about this summer’s landmark Wegovy heart health study
At some point this summer, the drugmaker Novo Nordisk will release results from a closely…
STAT+: With some savvy bets, a dynamic duo makes Eli Lilly one of pharma’s biggest success stories
The partnership that would shape Eli Lilly into one of the biggest success stories in…
STAT+: NIH halts funding for Colombian facilities accused of abusing animals
The U.S. National Institutes of Health late last month halted funding for a pair of…
STAT+: Pharmalittle: Novo Nordisk spent $11 million on doctors to promote Ozempic and similar drugs; China offers foreign drugmakers an olive branch
Good morning, everyone, and nice to see you again after an extended holiday break, at…
STAT+: Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic
WASHINGTON – Novo Nordisk spent $11 million on meals and travel for thousands of doctors…
STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial
LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy…
STAT+: Dexcom CEO on strategy for bringing continuous glucose monitoring to type 2 diabetes patients
For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors…
STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Bright Health sells Medicare Advantage plans to Molina for $600 million
Bright Health Group has agreed to sell its Medicare Advantage plans to its publicly traded…
STAT+: Pharmalittle: FDA approves BioMarin gene therapy for hemophilia A; former Pfizer worker charged with insider trading
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare details the structure of its new drug price negotiation program
WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation…
STAT+: Medicare’s new proposal to cover medical devices draws a mixed reaction
The medical device industry is split on whether a proposed new Medicare reimbursement pathway will…
.jpg)
STAT+: BioMarin wins approval for gene therapy to treat hemophilia A
The Food and Drug Administration on Thursday approved a gene therapy to treat people with…
STAT+: Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa
Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious…
STAT+: Former Pfizer statistician is charged with insider trading over Paxlovid clinical trial results
A former Pfizer statistician on Thursday was charged by U.S. authorities with insider trading for…
STAT+: Pharmalittle: Drug-wholesaler owner indicted for alleged role in diverting HIV medicines; Catalent linked to Regeneron drug rejection
Top of the morning to you. A delicious cool breeze and shiny sun are hovering…
STAT+: Drug wholesaler owner indicted for role in diverting Gilead and J&J HIV medicines
The owner of a pharmaceutical wholesaler has been indicted for his alleged role in distributing…
STAT+: Counter-culture or pharma: Group behind MDMA therapy for PTSD wrestles with its identity
DENVER — He could have been a rock star, a religious icon, the way ecstatic…
STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain
For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from…
STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions
A young girl, maybe 5 or 6 years old, had come into Yoram Unguru’s clinic…
STAT+: Protestors slam health insurance lobby for Medicare Advantage coverage restrictions
WASHINGTON — Hundreds of activists rallied today outside of the headquarters of the country’s largest…
STAT+: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines
A year after two major drugmakers sued a wholesaler for its alleged role in distributing…
STAT+: After late start, Eli Lilly starts pulling ahead in race for the $30 billion weight loss market
SAN DIEGO — It was Novo Nordisk’s Ozempic and Wegovy that set off a new…
STAT+: Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit
Eli Lilly agreed to pay $2.4 million as part of a settlement with the U.S….
STAT+: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Grail faces uphill battle to get Medicare to cover its cancer screening test
WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test…
STAT+: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?
The makers of minimally invasive surgical devices seemed poised to capture a wide swath of…
STAT+: U.K. agency declines to recommend Eli Lilly’s Mounjaro for type 2 diabetes
LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s…
STAT+: Fatty liver disease was alleviated by Lilly’s ‘triple-G’ obesity drug in small study
SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in…
STAT+: Illumina to lay off 10% of research and development team in bid to cut costs by $100 million
SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing…
Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial
SAN DIEGO — Ozempic and Wegovy became weight loss sensations by targeting a single hormone,…
STAT+: UnitedHealth wins $3.3 billion takeover of home health giant Amedisys
Home health and hospice chain Amedisys has chosen a new corporate owner. Amedisys and UnitedHealth…
STAT+: Shareholders elect director’s romantic partner to Biogen’s board
Biogen shareholders voted to add biotech executive Susan Langer, who is the romantic partner of…
STAT+: Pharmalittle: Nearly half of U.S. adults would spend $100 a month for weight loss drugs; Pfizer scraps an obesity pill
Good morning, everyone. and welcome to another working week. We hope the weekend respite was…
STAT+: In setback, Pfizer abandons one weight-loss pill and bets on another
Pfizer said Monday that it had discontinued clinical trials of a once-daily weight-loss pill whose…
STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs
Almost half of Americans would be willing to spend up to $100 a month for…
STAT+: As demand for Covid shots wanes, Moderna seeks its next success
Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight…
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or…
STAT+: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial
SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on…
STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: EU poised to reject Amylyx’s ALS drug, as the company vows an appeal
LONDON — European regulators are on the verge of rejecting an ALS drug from Amylyx…
STAT+: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac
GSK reached a settlement with a man who claimed its Zantac heartburn medication caused his…
STAT+: Using its Covid know-how, Color Health aims to make cancer screenings convenient
Color Health wants to take away any reason you might have for skipping screenings for…
STAT+: At a defunct power station, the U.K. and Moderna celebrate a partnership meant to be an engine for science
LONDON — Back in the 1950s, Battersea Power Station, a towering brick structure on the…
STAT+: FDA rejects Intercept’s NASH drug, prompting a pivot
The Food and Drug Administration rejected Intercept Pharmaceuticals’ investigational treatment for NASH on Thursday, derailing…
STAT+: Congress explores changes to the way Medicare pays doctors
Congress is taking early steps towards changing the way Medicare pays physicians. At a hearing…